BiondVax
-
BiondVax’s universal flu vaccine improves existing flu vaccines in elderly
BiondVax Pharmaceuticals announced positive results from its second Phase II clinical trial (BVX-005) of the Universal Influenza Vaccine (Multimeric-001) developed by Biondvax for improving existing flu vaccines in elderly.
BiondVax | 20 February 2012
-
Immunization begins for universal flu vaccine phase 2a
BiondVax begun to immunize subjects in a phase 2a clinical trial of the multimeric-001 universal flu vaccine candidate. The study will evaluate the safety and immunogenicity of the Multimeric-001 vaccine. The vaccine comprised a unique, propriet…
BiondVax | 31 October 2010
-
BiondVax Pharmaceuticals Completes Flu Vaccine Clinical Trial
BiondVax Pharmaceuticals, an Israeli biopharmaceutical company, has announced the success of the Phase I/II clinical trial of the company’s Multimeric-001 universal flu vaccine, in trials that were conducted at the Sourasky Medical Center in Tel Av…
BiondVax | 08 January 2010
